Snapdragon Chemistry announces extended partnership

Cambridge, MA's Kendall Square
Cambridge, MA's Kendall Square--Courtesy of Chris Bressoud CC BY-ND 2.0

Snapdragon CEO Matthew Bio

Snapdragon Chemistry is expanding its team, working space, and corporate partnership and has elected a new CEO in a major update from the privately held CRO.

First up, the Cambridge, MA-based continuous flow technology CRO has moved to new lab facilities at Bolton Street in Cambridge alongside its corporate partner, Zaiput Flow Technologies.

In a statement, the companies said this co-location will "enhance the collaboration of these strategic partners and accelerate the development of advanced continuous chemical manufacturing technologies and solutions."

Snapdragon has also completed a new investment round that will pay toward expanding its capabilities and technologies, as well as hiring new scientists. Financial details of the round were not disclosed.

Specifically, the CRO said it is expanding its reaction profiling and analytical capabilities to include additional in-line process analytical technologies, including real-time and automated feedback control of process parameters. Snapdragon is also expanding its computational modeling capabilities, using reaction-profiling data in order to deliver "right-first-time" reactor design.

As part of the expansion, Snapdragon has hired Dr. Eric Fang as director of chemistry, and added both PhD- and BS-level chemists. The company said it also plans to hire additional scientists and engineers in the near future.

Finally, Snapdragon has also elected a new president and CEO in Dr. Matthew Bio, who succeeds current president/CEO--and co-founder--Tim Jamison.

Jamison will continue as chairman and as scientific and technical adviser to Snapdragon. Co-founder Aaron Beeler will also continue to serve on the board of directors and as scientific and technical adviser.

The company offers services for continuous flow in pharmaceutical manufacturing, a process it says can help significantly reduce costs for the industry.

- check out the release

Image courtesy of Chris Bressoud CC BY-ND 2.0


Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.